James Mond
2021
In 2021, James Mond earned a total compensation of $1.1M as Former Executive Vice President, Chief Scientific Officer and Chief Medical Officer at ADMA Biologics, a 8% decrease compared to previous year.
Compensation breakdown
| Option Awards | $204,200 |
|---|---|
| Salary | $216,522 |
| Stock Awards | $129,250 |
| Other | $544,118 |
| Total | $1,094,090 |
Mond received $544.1K in other compensation, accounting for 50% of the total pay in 2021.
Mond also received $204.2K in option awards, $216.5K in salary and $129.3K in stock awards.
Rankings
In 2021, James Mond's compensation ranked 8,478th out of 12,415 executives tracked by ExecPay. In other words, Mond earned more than 31.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,478 out of 12,415 | 32nd |
Division Manufacturing | 3,759 out of 5,508 | 32nd |
Major group Chemicals And Allied Products | 1,664 out of 2,378 | 30th |
Industry group Drugs | 1,481 out of 2,099 | 29th |
Industry Biological Products, Except Diagnostic Substances | 326 out of 449 | 27th |
Source: SEC filing on April 28, 2022.
Mond's colleagues
We found two more compensation records of executives who worked with James Mond at ADMA Biologics in 2021.
News
ADMA Biologics CEO Adam Grossman's 2021 pay jumps 122% to $4.4M
April 28, 2022
ADMA Biologics CEO Adam Grossman's 2020 pay rises 15% to $2M
April 7, 2021
ADMA Biologics CEO Adam Grossman's 2019 pay rises 10% to $1.7M
April 29, 2020
ADMA Biologics CEO Adam Grossman's 2018 pay falls 42% to $1.6M
April 24, 2019